[ABIO] ARCA biopharma, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.95 Change: 0.25 (9.26%)
Ext. hours: Change: 0 (0%)

chart ABIO

Refresh chart

Strongest Trends Summary For ABIO

ABIO is in the long-term down -100% below S&P in 27 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Fundamental Ratios
Shares Outstanding EPS-1.89 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-1.22
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-75.74% ROE-82.82% ROI
Current Ratio11.19 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-60 K Cash From Investing Activities Cash From Operating Activities-3.11 M Gross Profit
Net Profit-2.74 M Operating Profit-2.74 M Total Assets13.26 M Total Current Assets12.67 M
Total Current Liabilities1.13 M Total Debt Total Liabilities1.13 M Total Revenue
Technical Data
High 52 week15.1 Low 52 week0.45 Last close9.41 Last change1.18%
RSI61 Average true range3 Beta0.65 Volume31.43 K
Simple moving average 20 days-1.33% Simple moving average 50 days21.11% Simple moving average 200 days162.63%
Performance Data
Performance Week-27.62% Performance Month61.96% Performance Quart33.02% Performance Half1343.69%
Performance Year652.8% Performance Year-to-date1675.47% Volatility daily17.29% Volatility weekly38.66%
Volatility monthly79.22% Volatility yearly274.43% Relative Volume952.22% Average Volume1.64 M
New High New Low

News

2019-06-04 07:09:25 | One Thing To Remember About The ARCA biopharma, Inc. NASDAQ:ABIO Share Price

2019-05-13 09:00:00 | ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure

2019-05-08 16:30:00 | ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update

2019-05-01 08:30:00 | GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure

2019-04-23 08:30:00 | ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial

2019-03-18 08:30:00 | Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology

2019-03-06 08:00:00 | Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine

2019-02-27 16:15:00 | ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update

2019-02-20 07:30:00 | ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug

2019-01-16 08:30:00 | Zosano Appoints Linda Grais M.D., J.D. to Board of Directors

2018-12-26 11:47:40 | ARCA biopharma, Inc. NASDAQ:ABIO Insiders Have Been Selling

2018-12-20 16:01:00 | ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial

2018-11-14 16:30:00 | ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update

2018-11-12 08:30:00 | GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden AFB Results Presented at American Heart Association 2018 Scientific Sessions

2018-11-05 08:30:00 | ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden AFB results selected for presentation at american heart association 2018 scientific sessions

2018-10-10 16:16:48 | Westminster biotech company receives second extension on delisting notice from Nasdaq

2018-09-18 08:30:00 | ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial

2018-08-09 16:15:00 | ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update

2018-08-03 09:45:00 | Marijuana Stocks: Biotech Stock Report: 3 Companies To Watch In August 2018

2018-07-31 12:15:00 | 3 Biotech Stocks in Focus on Tuesday

2018-07-31 08:30:00 | ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation

2018-06-19 07:05:00 | Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks

2018-06-11 08:10:00 | Today’s Research Reports on Stocks to Watch: Acorda Therapeutics and TrovaGene

2018-05-29 08:30:00 | GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress

2018-05-11 08:20:00 | Today’s Research Reports on Stocks to Watch: vTv Therapeutics and ARCA Biopharma

2018-05-10 08:30:00 | ARCA biopharma Announces Phase 2B GENETIC-AF Clinical Trial Results Selected for Late Breaking Oral Presentation at European Society of Cardiology Heart Failure 2018 World Congress

2018-05-10 07:15:00 | Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks

2018-05-08 16:15:00 | ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update

2018-04-23 08:30:00 | ARCA biopharma and Medtronic Extend Gencaro Clinical Trial Collaboration Agreement

2018-04-03 07:20:00 | Blog Exposure - Insmed Announced Submission of New Drug to FDA for Patients with Nontuberculous Mycobacterial Lung Disease

2018-03-22 16:30:00 | ARCA biopharma Announces Fiscal Year 2017 Financial Results and Provides Corporate Update

2018-02-27 15:00:29 | Here’s Why Arca Biopharma Inc ABIO Shares Are Skyrocketing Today

2018-02-26 14:18:06 | ARCA biopharma And ObsEva Just Put Out Clinical Trial Data

2018-02-26 08:00:00 | ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial

2018-01-23 17:13:19 | One Thing To Consider Before Buying ARCA biopharma Inc NASDAQ:ABIO

2018-01-08 08:30:00 | ARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial

2018-01-02 17:09:09 | What You Must Know About ARCA biopharma Inc’s NASDAQ:ABIO Major Investors

2017-12-08 18:13:07 | Interested In Healthcare? Why ARCA biopharma Inc ABIO May Be The Entry Point

2017-11-30 14:25:08 | How Much is ARCA biopharma Inc’s ABIO CEO Getting Paid?

2017-11-20 08:05:00 | ARCA Biopharma, European Patent for Gencaro and Q3 Review

2017-11-17 08:10:00 | Today’s Research Reports on Stocks to Watch: ARCA biopharma and Amicus Therapeutics

2017-11-16 08:30:00 | ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting

2017-11-09 16:05:00 | ARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business Update

2017-10-23 20:16:48 | ARCA biopharma Inc ABIO: How Does It Impact Your Portfolio?

2017-10-04 08:00:00 | Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Zogenix

2017-09-21 08:30:00 | ARCA biopharma to Present at the Sidoti & Company Fall 2017 Conference

2017-08-16 08:30:00 | ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial

2017-08-09 16:30:00 | ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis

2017-08-03 16:15:00 | ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update

2017-06-20 08:30:00 | ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis – DSMB Recommendation Anticipated in August 2017